Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-05-25 00:00:00 ET · period of report 2022-05-23 · accession 0001209191-22-031865 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-25 | 2022-05-23 | PCVX | Sauer Paul | SVP Process Dev, Manufacturing | S - Sale | $26.22 | -3,000 | 23.7K | -11% | -$78.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-23 | S | D | 3,000 | $26.22 | 23,687 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $25.72 to $26.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. (F3) Includes 1,562 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 17, 2022. |